Literature DB >> 19051326

No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies.

Cristiana E T da Costa1, Karoly Szuhai, Ronald van Eijk, Manja Hoogeboom, Raphael Sciot, Fredrik Mertens, Helga Björgvinsdóttir, Maria Debiec-Rychter, Ronald R de Krijger, Pancras C W Hogendoorn, R Maarten Egeler, Nicola E Annels.   

Abstract

The etiology of Langerhans cell histiocytosis (LCH), a disease characterized by uncontrolled proliferation of Langerhans cells, is unknown. Although some believe that LCH is reactive, others support a neoplastic origin. We tested the hypothesis that LCH is neoplastic by investigating potential consistent chromosomal aberrations in LCH cells. We used multiparameter DNA flow cytometry to analyze the DNA ploidy LCH cells in 20 cases, performed karyotype analysis in 31 cases, array-based comparative genomic hybridization (arrayCGH) and single nucleotide polymorphism (SNP) arrays with DNA from flow-sorted CD1a-positive and CD1a-negative cells in 19 cases. Ploidy analysis revealed diploid DNA content in all cases. The karyotype of all patients analyzed was normal, excluding the presence of balanced translocations. ArrayCGH and SNP arrays did not show genome abnormalities. Despite positive TP53 protein immunohistochemical staining, sequencing of exon 5 to 8 of p53 gene showed no alterations in 7 cases. This study strongly suggests that gross chromosomal abnormalities do not cause LCH. Although we cannot exclude cryptic point mutations in as yet unidentified genes, this study of 72 LCH cases shows that LCH may be the result of restricted oligoclonal stimulation rather than unlimited neoplastic proliferation. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19051326     DOI: 10.1002/gcc.20634

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

1.  Langerhans cell histiocytosis: malignancy or inflammatory disorder doing a great job of imitating one?

Authors:  Barbara A Degar; Barrett J Rollins
Journal:  Dis Model Mech       Date:  2009 Sep-Oct       Impact factor: 5.758

Review 2.  Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?

Authors:  Marie-Luise Berres; Miriam Merad; Carl E Allen
Journal:  Br J Haematol       Date:  2014-11-28       Impact factor: 6.998

Review 3.  Langerhans-Cell Histiocytosis.

Authors:  Carl E Allen; Miriam Merad; Kenneth L McClain
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

4.  New insights into the molecular pathogenesis of langerhans cell histiocytosis.

Authors:  Francesca M Rizzo; Mauro Cives; Valeria Simone; Franco Silvestris
Journal:  Oncologist       Date:  2014-01-16

5.  Frequent BRAFV600E mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis.

Authors:  Rui Wei; Zhongqing Wang; Xiaolin Li; Yigang Shu; Bin Fu
Journal:  Biomed Rep       Date:  2013-01-25

Review 6.  Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.

Authors:  Milen Minkov
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 7.  Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases.

Authors:  Marie-Luise Berres; Carl E Allen; Miriam Merad
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

8.  Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Authors:  Sara Zarnegar; Benjamin H Durham; Pallavi Khattar; Neerav N Shukla; Ryma Benayed; Mario E Lacouture; Ehud Lavi; David C Lyden; Eli L Diamond; Ira J Dunkel; Omar Abdel-Wahab
Journal:  Pediatr Blood Cancer       Date:  2017-07-27       Impact factor: 3.167

9.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

10.  Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.

Authors:  Sanda Alexandrescu; Nina Tatevian; Bogdan A Czerniak; Michael H Covinsky; Nadja K Burns; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2012-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.